AcelRx Pharma (ACRX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to AcelRx Pharma (ACRX) Reports In-Line Q3 EPS
November 15, 2021 6:46 AM EST
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with two life sciences-focused investment funds that are existing and new stockholders in AcelRx, for the sale of 17,500,000 shares of common stock and warrants exercisable for an... More
November 15, 2021 6:00 AM EST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of a definitive merger agreement to acquire Lowell Therapeutics, Inc. (Lowell), a privately held company, and reported its third quarter 2021 financial results.
Lowell, Niyad and LTX-608 Overview
Lowell is a privately held company developing Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital. Niyad is being studied under an investigational device... More
